Physiologically-Based Pharmacokinetics and Empirical Pharmacodynamic Modeling for Pediatric Henagliflozin Dosing: Clinical Insights for Chinese Patients
文献类型：期刊论文
| 作者 | Zhang, Xinyue6; Xue, Hao6; Xu, Jialei6; Ren, Ke6; Qian, Fangyi6; Zhang, Yifan5; Dou, Jingru4; Shen, Kai3; Zhu, Xiao6; Xiang, Xiaoqiang1,2,6 |
| 刊名 | PEDIATRIC DIABETES
 |
| 出版日期 | 2025 |
| 卷号 | 2025期号:1页码:19 |
| 关键词 | Chinese population henagliflozin pediatric dosing pharmacodynamic (PD) modeling physiologically-based pharmacokinetic (PBPK) modeling |
| ISSN号 | 1399-543X |
| DOI | 10.1155/pedi/8857248 |
| 通讯作者 | Xiang, Xiaoqiang(xiangxq@fudan.edu.cn) ; He, Qingfeng(qf_he@fudan.edu.cn) |
| 英文摘要 | Objective: This study aimed to present a quantitative modeling and simulation approach for oral henagliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor primarily metabolized by uridine diphosphate-glucuronosyltransferase (UGT) enzymes.Methods: A physiologically-based pharmacokinetic (PBPK) model for henagliflozin was developed using in vitro metabolism and clinical pharmacokinetic (PK) data, with validation across multiple contexts, including healthy adults, and hepatic impairment populations. Additionally, empirical pharmacodynamic (PD) modeling was employed to optimize pediatric dosing based on exposure-response relationships for urinary glucose excretion (UGE). Predicting henagliflozin exposure in pediatric patients poses challenges due to UGT enzyme ontogeny and the scarcity of clinical PK data in younger age groups. Using twofold acceptance criteria, model-predicted and observed drug exposures and PK parameters (area under the curve and peak concentration) were compared in diverse scenarios, including monotherapy in healthy adults (single/multiple doses), hepatic impairment, and extrapolation to pediatric age groups.Results: The PBPK model accurately captured observed exposures within a twofold range in both adults and adolescents, supporting the model's predictive utility. The verified PBPK and empirical PD models informed dosing recommendations in pediatric populations aged 1 month to 18 years, achieving henagliflozin exposures comparable to those in adult patients receiving a 5-10 mg dose.Conclusion: This study shows that PBPK and PD modeling effectively guide pediatric dosing of henagliflozin, reducing trial reliance and supporting real-world validation. |
| WOS关键词 | GLUCOSE COTRANSPORTER 2 ; DRUG-DRUG INTERACTION ; UDP-GLUCURONOSYLTRANSFERASE ; SELECTIVE INHIBITOR ; LIVER-CIRRHOSIS ; ENZYMES ; PREDICT ; SHR3824 |
| 资助项目 | Shanghai Pujiang Program |
| WOS研究方向 | Endocrinology & Metabolism ; Pediatrics |
| 语种 | 英语 |
| WOS记录号 | WOS:001546128200001 |
| 出版者 | WILEY |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/321153]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Xiang, Xiaoqiang; He, Qingfeng |
| 作者单位 | 1.State Key Lab Adv Drug Formulat Overcoming Deliver, Shanghai, Peoples R China 2.Quzhou Fudan Inst, Quzhou, Peoples R China 3.Jiangsu Hengrui Med Co Ltd, Shanghai, Peoples R China 4.UCL, Dept Chem, London WC1H OAJ, England 5.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai, Peoples R China 6.Fudan Univ, Sch Pharmaceut Sci, Dept Clin Pharm & Pharm Adm, Shanghai, Peoples R China |
| 推荐引用方式 GB/T 7714 | Zhang, Xinyue,Xue, Hao,Xu, Jialei,et al. Physiologically-Based Pharmacokinetics and Empirical Pharmacodynamic Modeling for Pediatric Henagliflozin Dosing: Clinical Insights for Chinese Patients[J]. PEDIATRIC DIABETES,2025,2025(1):19. |
| APA | Zhang, Xinyue.,Xue, Hao.,Xu, Jialei.,Ren, Ke.,Qian, Fangyi.,...&He, Qingfeng.(2025).Physiologically-Based Pharmacokinetics and Empirical Pharmacodynamic Modeling for Pediatric Henagliflozin Dosing: Clinical Insights for Chinese Patients.PEDIATRIC DIABETES,2025(1),19. |
| MLA | Zhang, Xinyue,et al."Physiologically-Based Pharmacokinetics and Empirical Pharmacodynamic Modeling for Pediatric Henagliflozin Dosing: Clinical Insights for Chinese Patients".PEDIATRIC DIABETES 2025.1(2025):19. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。